0001610717-24-000097.txt : 20240228 0001610717-24-000097.hdr.sgml : 20240228 20240228173116 ACCESSION NUMBER: 0001610717-24-000097 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240227 FILED AS OF DATE: 20240228 DATE AS OF CHANGE: 20240228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Symons Julian A. CENTRAL INDEX KEY: 0001824727 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39617 FILM NUMBER: 24697319 MAIL ADDRESS: STREET 1: C/O ALIGOS THERAPEUTICS, INC. STREET 2: ONE CORPORATE DRIVE, 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aligos Therapeutics, Inc. CENTRAL INDEX KEY: 0001799448 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (800) 466-6059 MAIL ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 form4.xml X0508 4 2024-02-27 0001799448 Aligos Therapeutics, Inc. ALGS 0001824727 Symons Julian A. C/O ALIGOS THERAPEUTICS, INC. ONE CORPORATE DRIVE, 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 true See Remarks false Stock Option (Right to Buy) 16.18 2024-02-27 4 D 0 200000 0 D 2021-01-01 2030-12-01 Common Stock 200000 0 D Stock Option (Right to Buy) 3.06 2024-02-27 4 D 0 105000 0 D 2022-03-04 2032-02-04 Common Stock 105000 0 D Stock Option (Right to Buy) 3.06 2024-02-27 4 D 0 26250 0 D 2025-02-04 2032-02-04 Common Stock 26250 0 D Stock Option (Right to Buy) 0.96 2024-02-28 4 A 0 58822 0 A 2030-12-01 Common Stock 58822 58822 D Stock Option (Right to Buy) 0.96 2024-02-28 4 A 0 74998 0 A 2032-02-04 Common Stock 74998 74998 D Stock Option (Right to Buy) 0.96 2024-02-28 4 A 0 18750 0 A 2032-02-04 Common Stock 18750 18750 D On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 200,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 58,822 shares, having an exercise price of $0.96 per share. On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 105,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 74,998 shares, having an exercise price of $0.96 per share. On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 26,250 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 18,750 shares, having an exercise price of $0.96 per share. The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date. Executive Vice President, Chief Scientific Officer /s/ Lesley Ann Calhoun, as attorney-in fact for Julian A. Symons 2024-02-28